 | • レポートコード：MRC2212D079 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、257ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の市場調査によると、2021年に636.56百万ドルであった世界の血漿交換治療法市場規模が、2022年には710.47百万ドルへ達する見通しです。また2027年までに年平均10.51%成長し、1,159.52ドル百万ドルへ拡大すると予想されています。本調査資料では、血漿交換治療法の世界市場を調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、技術別（遠心分離、膜分離）分析、疾患別（血液疾患、代謝疾患、腎臓疾患）分析、製品別（消耗品、機器）分析、エンドユーザー別（採血センター・血液成分プロバイダー、病院・輸血センター）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目を掲載しています。こちらの調査資料ではAsahi Kasei Medical Co., Ltd.、B. Braun Melsungen AG、Baxter International Inc.、Cerus Corporation、Charles River Laboratories International, Inc.、Fresenius Medical Care AG & Co. KGaA、Grifols, S.A.、Haemonetics Corporation、Infomed SA、Kaneka Corporation、Medica S.P.A.、Medicap Clinic GmbH、MEISE Medizintechnik GmbH、Miltenyi Biotec、Nikkiso Co., Ltdなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の血漿交換治療法市場規模：技術別 - 遠心分離方式血漿交換治療法の市場規模 - 膜分離方式血漿交換治療法の市場規模 ・世界の血漿交換治療法市場規模：疾患別 - 血液疾患における市場規模 - 代謝疾患における市場規模 - 腎臓疾患における市場規模 ・世界の血漿交換治療法市場規模：製品別 - 血漿交換治療法消耗品の市場規模 - 血漿交換治療法機器の市場規模 ・世界の血漿交換治療法市場規模：エンドユーザー別 - 採血センター・血液成分プロバイダーにおける市場規模 - 病院・輸血センターにおける市場規模 ・世界の血漿交換治療法市場規模：地域別 - 南北アメリカの血漿交換治療法市場規模 アメリカの血漿交換治療法市場規模 カナダの血漿交換治療法市場規模 ブラジルの血漿交換治療法市場規模 ... - アジア太平洋の血漿交換治療法市場規模 日本の血漿交換治療法市場規模 中国の血漿交換治療法市場規模 インドの血漿交換治療法市場規模 韓国の血漿交換治療法市場規模 台湾の血漿交換治療法市場規模 ... - ヨーロッパ/中東/アフリカの血漿交換治療法市場規模 イギリスの血漿交換治療法市場規模 ドイツの血漿交換治療法市場規模 フランスの血漿交換治療法市場規模 ロシアの血漿交換治療法市場規模 ... - その他地域の血漿交換治療法市場規模 ・競争状況 ・企業情報 |
The Global Therapeutic Plasma Exchange Market size was estimated at USD 636.56 million in 2021 and expected to reach USD 710.47 million in 2022, and is projected to grow at a CAGR 10.51% to reach USD 1,159.52 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Therapeutic Plasma Exchange to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Technology, the market was studied across Centrifugation and Membrane Separation.
Based on Indication, the market was studied across Hematologic Disorders, Metabolic Disorders, Neurological Disorders, and Renal Disorders. The Hematologic Disorders is further studied across Atypical Hemolytic Uremic Syndrome, Hyperviscosity Syndrome, Severe/Symptomatic Cryoglobulinemia, and Thrombotic Thrombocytopenic Purpura. The Neurological Disorders is further studied across Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barré Syndrome, Multiple Sclerosis, Myasthenia Gravis, and PANDAS. The Renal Disorders is further studied across Antibody-mediated Renal Transplant Rejection, Goodpasture Syndrome, and Wegener’s Granulomatosis.
Based on Product, the market was studied across Consumables and Devices.
Based on End-user, the market was studied across Blood Collection Centers & Blood Component Providers and Hospitals & Transfusion Centers.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across Alaska, California, Florida, Illinois, Massachusetts, Michigan, Montana, Nevada, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Therapeutic Plasma Exchange market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Therapeutic Plasma Exchange Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Therapeutic Plasma Exchange Market, including Asahi Kasei Medical Co., Ltd., B. Braun Melsungen AG, Baxter International Inc., Cerus Corporation, Charles River Laboratories International, Inc., Fresenius Medical Care AG & Co. KGaA, Grifols, S.A., Haemonetics Corporation, Infomed SA, Kaneka Corporation, Medica S.P.A., Medicap Clinic GmbH, MEISE Medizintechnik GmbH, Miltenyi Biotec, Nikkiso Co., Ltd., Pall Corporation, Qingdao Haier Biomedical Co., Ltd, Sb-Kawasumi Laboratories, Inc., and Terumo BCT, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Therapeutic Plasma Exchange Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Therapeutic Plasma Exchange Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Therapeutic Plasma Exchange Market?
4. What is the competitive strategic window for opportunities in the Global Therapeutic Plasma Exchange Market?
5. What are the technology trends and regulatory frameworks in the Global Therapeutic Plasma Exchange Market?
6. What is the market share of the leading vendors in the Global Therapeutic Plasma Exchange Market?
7. What modes and strategic moves are considered suitable for entering the Global Therapeutic Plasma Exchange Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Need of Therapeutic Plasma Exchange due to Rise in Prevalence of Autoimmune and Cardiac Diseases
5.1.1.2. Technical Advancement in Apheresis Technologies
5.1.2. Restraints
5.1.2.1. Cost Associated with the Devices and Therapeutic Plasma Exchange Procedures
5.1.3. Opportunities
5.1.3.1. Advancement in Therapeutic Plasma Exchange Technology and its Immunomodulatory Effect in Neuromuscular Diseases
5.1.3.2. Surge in Demand for Therapeutic Plasma Exchange (TPE) in Pediatric Intensive Care
5.1.4. Challenges
5.1.4.1. Complications Associated with the Apheresis Procedure in TPE
5.2. Cumulative Impact of COVID-19
6. Therapeutic Plasma Exchange Market, by Technology
6.1. Introduction
6.2. Centrifugation
6.3. Membrane Separation
7. Therapeutic Plasma Exchange Market, by Indication
7.1. Introduction
7.2. Hematologic Disorders
7.3.1. Atypical Hemolytic Uremic Syndrome
7.3.2. Hyperviscosity Syndrome
7.3.3. Severe/Symptomatic Cryoglobulinemia
7.3.4. Thrombotic Thrombocytopenic Purpura
7.3. Metabolic Disorders
7.4. Neurological Disorders
7.5.1. Chronic Inflammatory Demyelinating Polyneuropathy
7.5.2. Guillain-Barré Syndrome
7.5.3. Multiple Sclerosis
7.5.4. Myasthenia Gravis
7.5.5. PANDAS
7.5. Renal Disorders
7.6.1. Antibody-mediated Renal Transplant Rejection
7.6.2. Goodpasture Syndrome
7.6.3. Wegener’s Granulomatosis
8. Therapeutic Plasma Exchange Market, by Product
8.1. Introduction
8.2. Consumables
8.3. Devices
9. Therapeutic Plasma Exchange Market, by End-user
9.1. Introduction
9.2. Blood Collection Centers & Blood Component Providers
9.3. Hospitals & Transfusion Centers
10. Americas Therapeutic Plasma Exchange Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Therapeutic Plasma Exchange Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Therapeutic Plasma Exchange Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Asahi Kasei Medical Co., Ltd.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. B. Braun Melsungen AG
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Baxter International Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Cerus Corporation
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Charles River Laboratories International, Inc.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Fresenius Medical Care AG & Co. KGaA
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Grifols, S.A.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Haemonetics Corporation
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Infomed SA
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Kaneka Corporation
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Medica S.P.A.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Medicap Clinic GmbH
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. MEISE Medizintechnik GmbH
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Miltenyi Biotec
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Nikkiso Co., Ltd.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Pall Corporation
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Qingdao Haier Biomedical Co., Ltd
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Sb-Kawasumi Laboratories, Inc.
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Terumo BCT, Inc.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing